OTC · Biotechnology

Newron Pharmaceuticals S.p.A. (NWPHF) Stock

$20.00 +0.00% OTC: NWPHF Healthcare

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions.

Valuation

MetricValue
Price$20.00
Market Cap$416.12M
P/E Ratio-19.32
P/B Ratio-23.35
P/S Ratio14.15
EPS (TTM)$-0.66
52-Week High$20.00
52-Week Low$9.36
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE277.88%
ROA-33.13%
ROCE46.75%
Gross Margin99.94%
Operating Margin-24.59%
Net Margin-69.29%
Debt/Equity-3.43
Current Ratio0.76

Annual Financials (USD)

Metric20212022202320242025
Revenue$6.0M$6.0M$9.0M$51.0M$19.0M
Operating Profit$-12.0M$-13.0M$-12.0M$26.0M$-5.0M
Net Profit$-15.0M$-17.0M$-16.0M$16.0M$-13.0M
EPS$-0.84$-0.98$-0.91$0.85$-0.66
Op Margin-214.5%-218.3%-128.4%50.9%-24.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$50.0M$37.0M$26.0M$64.0M$40.0M
Total Liabilities$47.0M$51.0M$56.0M$62.0M$51.0M
Cash$25.0M$13.0M$6.0M$7.0M$12.0M
Borrowings$43.0M$46.0M$48.0M$50.0M$38.0M

Latest News

Newron Provides Update Following Type A Meeting With the FDA Business Wire · Jul 2, 2026 European Growth Leaders With High Insider Ownership Simply Wall St. · May 6, 2026 European Growth Stocks With Insider Influence May 2026 Simply Wall St. · May 6, 2026 European Growth Companies With High Insider Ownership In May 2026 Simply Wall St. · May 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-11.0M$-10.0M$-18.0M$32.0M
Investing Cash Flow$8.0M$0$3.0M$6.0M$-14.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$12.0M$-12.0M$-7.0M$1.0M$5.0M
Free Cash Flow$-11.0M$-11.0M$-10.0M$-18.0M$32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.11
EV / EBITDA-65.44
FCF Yield11.81%
Quick Ratio0.76
Interest Coverage-1.15
Return 1Y113.68%
Return 3Y852.38%
Return 5Y—

Ownership

Insiders Held13.11%
Institutions Held9.50%
Institutions Float Held10.93%
Institutional HolderSharesReport Date
American Century ETF Trust-Avantis International Equity ETF41,3732026-06-30
American Century ETF Trust-Avantis International Equity Fund2,3582026-03-31
iShares Trust-iShares Neuroscience and Healthcare ETF1,0602026-06-30
American Century ETF TRT-Avantis Responsible Intl Eqy. ETF302026-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing treatments for disorders affecting the central and peripheral nervous systems, as well as pain conditions. Operating in both Italy and the United States, the company's portfolio includes Xadago (safinamide), an approved therapy for Parkinson's disease, which is also under investigation for levodopa-induced dyskinesia. Additionally, Newron is developing Evenamide for schizophrenia and its treatment-resistant form, and Ralfinamide for specific orphan indications in neuropathic pain. Established in 1999, Newron Pharmaceuticals S.p.A. maintains its headquarters in Bresso, Italy.

Newron Pharmaceuticals S.p.A. is headquartered in IT.

Newron Pharmaceuticals S.p.A. (NWPHF) stock trades at $20.00 with a market capitalization of $416.12M. The stock is valued at a price-to-earnings (P/E) ratio of -19.32, price-to-book of -23.35, price-to-sales of 14.15. Over the past 52 weeks the stock has ranged between $9.36 and $20.00, and currently trades at its 52-week high.

On profitability, Newron Pharmaceuticals S.p.A. generates a return on equity (ROE) of 277.88% — well above the market average, a sign of a high-quality business, return on capital employed of 46.75%, an operating margin of -24.59%, a net profit margin of -69.29%.

Official website: www.newron.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides